Media, page-12

Study Design

Go to

	Study Type:	Interventional (Clinical Trial)
1	ActualEnrollment:	88 participants
2	Allocation:	Randomized
3	Intervention Model:	Parallel Assignment
4	Masking:	None (Open Label)
5	Primary Purpose:	Treatment
6	Official Title:	A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer
7	ActualStudy Start Date:	July 2, 2018
8	ActualPrimary Completion Date:	February 27, 2020
9	EstimatedStudy Completion Date:	August 31, 2021

interesting timing of patent approval with study completion date iminent